Send to

Choose Destination
Vaccine. 2013 Aug 20;31(37):3778-82. doi: 10.1016/j.vaccine.2013.04.079. Epub 2013 May 15.

Interferon-gamma production by mononuclear cells in Bacille Calmette-Guérin-revaccinated healthy volunteers predicted long-term antimycobacterial responses in a randomized controlled trial.

Author information

Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon, s/n, Vale do Canela, 40110-902 Salvador, Bahia, Brazil.


The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine currently available for tuberculosis, and it demonstrates variable efficacy against the disease. The assessment of new vaccine strategies is hindered by the small annual probability that an infected individual will develop tuberculosis, and the lack of simple and reliable surrogate markers of protection. The frequency of cytokine-producing T cells as well as the production of IFN-γ have been disputed as surrogate markers of protection. We evaluated the evolution of these immune parameters in a population from a high burden city where BCG revaccination has been shown to result in mild protection. We found that individuals whose in vitro IFN-γ responses to mycobacterial antigens had increased by more than 3.3-fold were more likely to maintain higher responses after 1 year and to show increased expansion of IFN-γ-producing T lymphocytes than those with lower or null increase of IFN-γ.


BCG; Bacille of Calmette-Guérin; CI; Correlates of protection; HIV; Human populations; IFN-γ; IL; M. tuberculosis H37Rv culture lysate; Mtb; PBMC; PHA; PPD; Receiver operating characteristic; TB; TNF; TST; Tuberculosis vaccines; Vaccine evaluation; confidence interval; human immunodeficiency virus; interferon-gamma; interleukin; peripheral blood mononuclear cells; phytohemagglutinin; protein purified derivative; roc; tuberculin skin test; tuberculosis; tumor necrosis factor.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center